Multi-cytokine inhibitor that prevents IL-2, IL-9, and IL-15 from interacting with the gamma receptor subunit CD132. Wang et al. (81) demonstrated that treating T-LGLL cell lines and primary patient samples with BNZ-1 led to reduced tumor cell viability, decreased downstream signaling, and increased apoptosis. Additionally, Brammer et al. (83) showed apoptosis of LGLL cells in patients treated with BNZ-1 within 24 h of treatment. A phase I/II clinical trial (NCT03239392) showed a 90% decline in T and NK cells by day 15 of treatment (82). Here, IL2 is linked to neoplasm.